Table 1.
(C): Group 3 (structural abnormalities involving chromosomes 1, 3, 6, 9, 10, 11, 12, and 17).
| Patient/sex/age at diagnosis | Karyotype | Spleen size(cm) | % blast in PB | Platelet count(×103/µL) | Disease progression | CyR | Interval* in months | Last status |
|---|---|---|---|---|---|---|---|---|
| 19(F/32) | 46,XX,t(9;22)(q34;q11),del(11)(p13)[17] | 17 | 4 | 221 | Myeloid blast | No | 32 | Dead |
| 20(F/24) | 46,XX,t(9;22)(q34;q11)[5]/46,XX,+1,del(1)(p13),der(7)t(1;7)(q31;p22),del(9)(q13),t(9;22)(q34;q11),-19[2] | 24 | 40 | 594 | No | No | 19 | Alive |
| 21(F/50) | 46,XX,t(9:22)(q34;q11)[9]/46,idem,t(12;17)(p13;q21) [6] | 23 | 5 | 1477 | AP | No | 42 | Dead |
| 22(F/52) | 46,XX,t(9;22)(q34;q11)[20]/46,idem,ins(10)(p15q25q26)[2]/46,XX[3] | 4 | No | 101 | AP | No | 13 | Dead |
| 23(F/46) | 46,XX,t(9;22)(q34;q11)[2]/46,XX,t(9;22)(q34;q11),der(9)t(9;12)t(p24;p13)[15] | 10 | No | 112 | Myeloid blast | No | 9 | Dead |
| 24(F/37) | 46,XX,del(1)(p32) [11]/46,idem,t(9;22)(q34;q11)[2] | 13 | No | 457 | Myeloid blast | No | 83 | Dead |
| 25(M/18) | 46,XY,t(1;11)(q22;p12),t(9;22)(q34;q11)[23] | 27 | No | 331 | No | Complete | 0 | Alive |
| 26(F/63) | 46,XX,t(9;22)(q34;q11)[8]/46,idem,t(3;15;21)(q25;q22;q22) [13] | 6 | No | 132 | Myeloid blast | No | 0 | Dead |
| 27(M/57) | 46,XY,del(3)(q27)[15] | 11 | 2 | 436 | No | Complete | 8 | Alive |
| 28(M/20) | 43~46,XY,del(6)(p21)[4],t(9;22)(q34;q11)[4], -19[4],+22[3][cp4] | 25 | No | 611 | No | No | 0 | Alive |
*Interval (month) between CML diagnosis and emergence of ACAs.
PB, peripheral blood; CyR, cytogenetic response; AP, accelerated phase.